Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?

BACKGROUND: A cost-minimization analysis (CMA) was performed to estimate the economic impact of introducing the SQ house dust mite sublingual immunotherapy (SQ HDM SLIT)-tablet marketed as ACARIZAX™ (regulatory approval May 2017) for the treatment of HDM-induced allergic rhinitis in Canada (Ontario...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Anne K., Gagnon, Rémi, Hammerby, Eva, Lau, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487002/
https://www.ncbi.nlm.nih.gov/pubmed/31061666
http://dx.doi.org/10.1186/s13223-019-0344-3